155 related articles for article (PubMed ID: 37603928)
1. Real-world persistence to first-line DMTs in relapsing-remitting multiple sclerosis.
López-Caneda C; Pérez-Haro MJ; Sánchez-Franco C; Álvarez-Rodríguez E; Aguado-Valcárcel M; Marcos-Bobillo M; González-Suarez I
Mult Scler Relat Disord; 2023 Oct; 78():104909. PubMed ID: 37603928
[TBL] [Abstract][Full Text] [Related]
2. An analysis of first-line disease-modifying therapies in patients with relapsing-remitting multiple sclerosis using the French nationwide health claims database from 2014-2017.
Vermersch P; Suchet L; Colamarino R; Laurendeau C; Detournay B
Mult Scler Relat Disord; 2020 Nov; 46():102521. PubMed ID: 32977077
[TBL] [Abstract][Full Text] [Related]
3. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
[TBL] [Abstract][Full Text] [Related]
4. Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register.
Zanghì A; Avolio C; Amato MP; Filippi M; Trojano M; Patti F; Amico E;
Mult Scler Relat Disord; 2022 Feb; 58():103489. PubMed ID: 35032879
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.
Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
JAMA Neurol; 2018 Mar; 75(3):320-327. PubMed ID: 29309484
[TBL] [Abstract][Full Text] [Related]
6. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry.
Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V;
Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114
[TBL] [Abstract][Full Text] [Related]
7. Adherence and discontinuation rates in patients on Tecfidera™ (dimethyl fumarate): Long-term Canadian experience from the Biogen ONE™ support program.
Thompson MT; Virginia D; Nick B; Melissa G; Engineer N; Shen C; Reedie S
Mult Scler Relat Disord; 2022 Nov; 67():104080. PubMed ID: 35973386
[TBL] [Abstract][Full Text] [Related]
8. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study.
Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V
Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463
[TBL] [Abstract][Full Text] [Related]
9. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
Neuberger EE; Abbass IM; Jones E; Engmann NJ
Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
[TBL] [Abstract][Full Text] [Related]
10. Real-life outcomes for oral disease-modifying treatments of relapsing-remitting multiple sclerosis patients: Adherence and adverse event profiles from Marmara University.
Vural E; Engin E; Sünter G; Yıldırım KA; Günal D
Turk J Med Sci; 2023 Jun; 53(3):771-779. PubMed ID: 37476900
[TBL] [Abstract][Full Text] [Related]
11. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
[TBL] [Abstract][Full Text] [Related]
12. Long-term persistence with injectable therapy in relapsing-remitting multiple sclerosis: an 18-year observational cohort study.
Zhornitsky S; Greenfield J; Koch MW; Patten SB; Harris C; Wall W; Alikhani K; Burton J; Busche K; Costello F; Davenport JW; Jarvis SE; Lavarato D; Parpal H; Patry DG; Yeung M; Metz LM
PLoS One; 2015; 10(4):e0123824. PubMed ID: 25867095
[TBL] [Abstract][Full Text] [Related]
13. Persistence, Adherence, and Switching to Higher-Cost Therapy in Patients with Multiple Sclerosis Initiating Oral Disease-Modifying Therapies: A Retrospective Real-World Study.
Araujo L; Geertsen SS; Amedume A; Higuchi K; van Wingerden J
Neurol Ther; 2022 Dec; 11(4):1735-1748. PubMed ID: 36152222
[TBL] [Abstract][Full Text] [Related]
14. Predictors of first-line treatment persistence in a Portuguese cohort of relapsing-remitting multiple sclerosis.
Correia I; Marques IB; Sousa M; Batista S; Ferreira R; Nunes C; Macário C; Cunha L; Sousa L
J Clin Neurosci; 2016 Nov; 33():73-78. PubMed ID: 27542939
[TBL] [Abstract][Full Text] [Related]
15. First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence.
Ferraro D; Camera V; Baldi E; Vacchiano V; Curti E; Guareschi A; Malagù S; Montepietra S; Strumia S; Santangelo M; Caniatti L; Foschi M; Lugaresi A; Granella F; Pesci I; Motti L; Neri W; Immovilli P; Montanari E; Vitetta F; Simone AM; Sola P
Curr Med Res Opin; 2018 Oct; 34(10):1803-1807. PubMed ID: 29526118
[TBL] [Abstract][Full Text] [Related]
16. Real-world persistence of multiple sclerosis disease-modifying therapies.
Tallantyre EC; Dobson R; Froud JLJ; St John FA; Anderson VM; Arun T; Buckley L; Evangelou N; Ford HL; Galea I; George S; Gray OM; Hibbert AM; Hu M; Hughes SE; Ingram G; Kalra S; Lim CE; Mathews JTM; McDonnell GV; Mescall N; Norris S; Ramsay SJ; Rice CM; Russell MJ; Shawe-Taylor MJ; Williams TE; Harding KE; Robertson NP
Eur J Neurol; 2024 Jul; 31(7):e16289. PubMed ID: 38567516
[TBL] [Abstract][Full Text] [Related]
17. A Real-World Experience of Azathioprine Versus First-Line Disease-Modifying Therapy in Relapsing-Remitting Multiple Sclerosis-A Prospective Cohort Study.
Agrawal A; Srivastava MVP; Bhatia R; Goyal V; Singh MB; Vishnu VY; Prabhakar A
Brain Sci; 2023 Aug; 13(9):. PubMed ID: 37759850
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of switching to teriflunomide in older patients with relapsing multiple sclerosis: A real-world retrospective multicenter analysis.
Berkovich R; Negroski D; Wynn D; Sellers D; Bzdek KG; Lublin AL; Rawlings AM; Quach C; Wells DP; Dumlao M; Bora A; Ranno AE; Luo KL; Chavin J; Hua LH; Becker D
Mult Scler Relat Disord; 2023 Feb; 70():104472. PubMed ID: 36566698
[TBL] [Abstract][Full Text] [Related]
19. Dimethyl fumarate and teriflunomide for multiple sclerosis in a real-life setting: a French retrospective cohort study.
Condé S; Moisset X; Pereira B; Zuel M; Colamarino R; Maillet-Vioud M; Lauxerois M; Taithe F; Clavelou P;
Eur J Neurol; 2019 Mar; 26(3):460-467. PubMed ID: 30320947
[TBL] [Abstract][Full Text] [Related]
20. Injectable Versus Oral First-Line Disease-Modifying Therapies: Results from the Italian MS Register.
D'Amico E; Zanghì A; Romeo M; Cocco E; Maniscalco GT; Brescia Morra V; Paolicelli D; De Luca G; Galgani S; Amato MP; Salemi G; Inglese M; Confalonieri PA; Lus G; Avolio C; Gallo A; Vianello M; Onofrj M; Filippi M; Trojano M; Patti F
Neurotherapeutics; 2021 Apr; 18(2):905-919. PubMed ID: 33528815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
